Related Experiment Video

Updated: Jun 12, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Treatment of dyslipidemia in HIV-infected patients

Rajagopal V Sekhar1, Ashok Balasubramanyam

  • 1Translational Metabolism Unit, Diabetes and Endocrinology Research Center, Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, Houston, TX 77030-2600, USA.

Expert Opinion on Pharmacotherapy
|May 22, 2010
PubMed

Insights

Managing dyslipidemia in HIV patients is complex. This review details the pathophysiology and evidence-based strategies, including lifestyle changes and pharmacotherapy, for effective treatment.

Area of Science:

  • Cardiology
  • Endocrinology
  • Infectious Diseases

Background:

  • HIV-infected individuals face elevated risks of dyslipidemia, insulin resistance, and cardiovascular disease.
  • Current therapeutic strategies for these conditions are often complex, debated, and inconsistently effective.

Purpose of the Study:

  • To provide a comprehensive overview of the pathophysiology of lipid abnormalities in HIV.
  • To outline evidence-based and expert-opinion-driven therapeutic approaches for managing dyslipidemia in HIV patients.

Main Methods:

  • Discussion of the pathophysiology of altered lipid profiles (triglycerides, LDL-C, HDL-C) and insulin resistance in HIV.
  • Review of lifestyle interventions, conventional pharmacotherapy (statins, fibrates, niacin, thiazolidinediones), and novel treatments (omega fatty acids, acipimox, growth hormone, leptin).

Main Results:

  • A thorough understanding of the underlying mechanisms driving lipid abnormalities in HIV.
  • A rational, evidence-based framework for the therapeutic management of dyslipidemia in this population.

Conclusions:

  • Treating dyslipidemia in HIV patients presents significant challenges, including potential drug interactions.
  • Effective management necessitates a deep grasp of pathophysiology and therapeutic principles, integrating lifestyle modifications and appropriate pharmacological agents.
Abstract

More Related Videos

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...